Archive for the ‘Regenerative Medicine’ Category

WINSTON-SALEM, N.C., Nov. 7, 2012 /PRNewswire/ --Tengion, Inc. (TNGN), a leader in regenerative medicine, today announced that John Miclot, President and Chief Executive Officer of Tengion, will present at the upcoming Lazard Capital Markets 9th Annual Healthcare Conference on Wednesday, November 14, 2012, at 11:30 a.m. EST in New York City.

A live audio webcast of the presentation can be accessed at http://www.wsw.com/webcast/lz13/tngn or under "Calendar of Events" in the Investors section of the Company's website at http://www.tengion.com. A replay of the presentation will be available on Tengion's website for 90 days. Investors interested in listening to the live webcast should log on before the start time in order to download any software required.

About Tengion

Tengion, a clinical-stage regenerative medicine company, is focused on developing its Organ Regeneration Platform to harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues with the goal of delaying or eliminating the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. An initial clinical trial is ongoing for the Company's most advanced product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like urinary tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company's lead preclinical candidate is the Neo-Kidney Augment, which is designed to prevent or delay dialysis kidney transplantation by increasing renal function in patients with advanced chronic kidney disease. Tengion has worldwide rights to its product candidates.

Visit link:
Tengion to Present at the Lazard Capital Markets 9th Annual Healthcare Conference

Gov. Rick Perry today highlighted Texas leading role in the advancement of regenerative medicine to produce safe, effective and ethical adult stem cell therapies. The governor spoke at the inaugural Houston Stem Cell Summit, which focuses on adult stem cell research and its potential to tackle life-threatening diseases.

Im proud Texas is playing a key role in the advancement of adult stem cell research and therapies, both of which are promising for patients and our economy, Gov. Perry said. This conference represents another step in the growth of this industry that I hope and expect will be centered right here in the Lone Star State.

Texas has taken clear steps to advance research in ethical regenerative medicine as quickly and safely as possible, while protecting patients receiving these treatments in the state. Earlier this year, the Texas Legislature, Texas Medical Board and Texas Department of Health and Human Services set up a regulatory framework to guide companies, institutions and physicians collaborating to produce effective stem cell research.

Additionally, Texas continues to attract top researchers in biotechnology and regenerative medicine thanks to our commitment to investing in the technologies of the future through the Cancer Prevention Research Institute of Texas (CPRIT) and Texas Emerging Technology Fund (TETF). CPRIT has funded 427 awards totaling more than $756 million for cancer research, commercialization and prevention in academic institutions, non-profit organizations and private companies. The TETF has invested more than $180 million in grant-matching and research superiority funds in Texas universities, and more than $194 million in 137 early-stage companies, with more than $103 million of that going directly to biotechnology and life science companies.

Texas researchers have also received more than $52 million in National Institute of Health (NIH) funding in 2009 for adult stem cell studies. These grants have resulted in the Austin Heart Hospital successfully treating heart attack patients with adult stem cells, and success in treating spinal cord injuries and a variety of heart conditions.

The Houston Stem Cell Summit highlights the latest research and breakthroughs regarding the use of adult stem and progenitor cell therapies. The summit covers all aspects of emerging stem cell therapies including the latest in peer reviewed academic stem cell research, breakthroughs in adult stem cell therapies, patient experiences, the business of stem cell therapies and the evolving regulatory environment for stem cell therapies. For more information, please visit http://www.stemcellsummit.com/houston/. To view the governors full remarks, please visit http://governor.state.tx.us/news/speech/17803/

Original post:
Texas Can Become Center for Regenerative Medicine

454: A Documentary About Stem Cell Research
In 2004 Alex Goldberg, then a 20 year old local filmmaker began a documentary on stem cell research at the University of Washington. On June 16 2011, he died before the film was finished. This film highlights the need for this research to continue in order to save thousands of lives. In this unsettling political climate, the film resonates. It was made during the Bush era when stem cell lines were limited, thus stunting the research and in turn a cure for so many diseases. Many thanks to Dr Charles Murry and his staff for their tireless efforts to create therapies in regenerative medicine. Dr Murry may be reached through the University of Washington research labs. If you would like to make donations to help fund this research and the researchers who work without appropriate compensation please click the following link: depts.washington.eduFrom:Leta GoldbergViews:67 2ratingsTime:15:03More inEducation

See the original post here:
454: A Documentary About Stem Cell Research - Video

MARLBOROUGH, Mass.--(BUSINESS WIRE)--

Advanced Cell Technology, Inc. (ACT, OTCBB: ACTC or the Company), a leader in the field of regenerative medicine announced today that it will release its third quarter 2012 financial results on Thursday, November 8th after the market closes. The Company will hold a conference call at 4:30 p.m. EST that day during which it will discuss its results and provide a corporate update.

Interested parties may dial (888) 264-3177 or 706-902-4345 using reference conference ID number 90962762. The call will be available live and for replay by webcast at: http://us.meeting-stream.com/advancedcelltechnology110812 .

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visitwww.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words will, believes, plans, anticipates, expects, estimates, and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the companys periodic reports, including the report on Form 10-K for the year ended December 31, 2011. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Companys clinical trials will be successful.

See the rest here:
Advanced Cell Technology to Announce Third Quarter Financial Results on Thursday, November 8th

Denver, CO (PRWEB) November 05, 2012

The American Institute of Architects has recognized Curtis Fentress as the 2012 Colorado Architect of the year and acknowledged two of Fentress Architects most innovative designs. The Sanford Consortium for Regenerative Medicine has won both the 2012 AIA Colorado Honor Award for Built Architecture and the 2012 AIA Denver Merit Award for Built Architecture. Mineta-San Jose International Airport Terminal B has won the 2012 AIA Colorado Merit Award for Built Architecture.

Were deeply honored and humbled by these awards, said Curtis Fentress. Its a testament to the artistry and dedication of our teams. Theyre the ones who turned these ideas into reality.

Curtis Fentress, FAIA, RIBA

Awarded: 2012 AIA Colorado Architect of the Year

Curtis Fentress career illustrates how design excellence can elevate and transform the publics understanding and experience of architecture. Fentress body of work is replete with projects uniquely appropriate to their communities architecture with humanism at its heart, designed to stand the test of time. For over three decades, Curtis Fentress and his team have focused on designing enduring public architecture, applying the firms expertise and resources to elevate the human experience in public buildings.

His buildings are keenly aligned with their environmental context, culture and intent. His design philosophy developed through work on Colorado projects such as 1999 Broadway, with its blend of modernist elements that never the less relate to the historic nature of the Holy Ghost Church with which it shares space; Denver International Airport, which quickly became a regional icon and one of the most recognized airports in the world; and vital life-safety work on the beloved Colorado State Capitol. In 2009, Fentress was the first and only architect to be inducted into the Visit Denver Tourism Hall of Fame, honoring the impact his projects have had on the physical, economic and civic landscapes of the region.

Under his direction, Fentress Architects has won more than 400 awards and accolades, including 80 awards from his peers in the AIA, and has won 34 national and international competitions. A Fellow of the AIA, Fentress and his firm have designed $27 billion of architectural projects worldwide, visited by over 350 million people annually. He serves widely as a lecturer at colleges and universities throughout the United States and abroad.

Sanford Consortium for Regenerative Medicine

Awarded: 2012 AIA Colorado Honor Award for Built Architecture; 2012 AIA Denver Merit Award for Built Architecture

Read the original:
Fentress Architects Take Home Three Prestigious Design Awards and Colorado Architect of the Year

NORTHRIDGE, CA and CAMBRIDGE, UNITED KINGDOM--(Marketwire - Nov 5, 2012) - Regenerative medicine company Avita Medical Ltd. ( ASX : AVH ) ( OTCQX : AVMXY ) today announced that it will be presenting at the upcoming SoCalBio Investor Conference & Exhibition. The event will take place on November 7, 2012 at the Omni Hotel in Los Angeles, California.

The Company will be presenting in the Wound Healing & Regenerative Medicine Group.

"We are pleased to be presenting at this quality bioscience industry conference," said Dr. William Dolphin, Avita Medical's CEO. "ReCell SprayOn Skin is on the market in other countries and undergoing FDA clinical trials in the US. This conference is a great venue to generate awareness among the US investment community as we approach FDA submission."

This is a one-day conference organized annually by the Southern California Biomedical Council (SoCalBio) to showcase the strength and future of the bioscience industry in Los Angeles/Orange County and neighboring communities. For more information on the conference: http://www.socalbio.org/SocalBio_2012/home_2012.htm

ABOUT AVITA MEDICAL LTD. Avita Medical (http://www.avitamedical.com/) develops and distributes regenerative and tissue-engineered products for the treatment of a broad range of wounds, scars and skin defects. Avita's patented and proprietary tissue-culture, collection and application technology provides innovative treatment solutions derived from a patient's own skin. The company's lead product, ReCell Spray-On Skin, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE-marked for Europe, TGA-registered in Australia, and SFDA-cleared in China. ReCell is on market and generating early revenues. ReCell is not available for sale in the United States; in the US ReCell is an investigational device limited by federal law to investigational use. A Phase III FDA trial is in process.

Original post:
Avita Medical to Present at SoCalBio Investor Conference & Exhibition

Public release date: 5-Nov-2012 [ | E-mail | Share ]

Contact: Katie Pence katie.pence@uc.edu 513-558-4561 University of Cincinnati Academic Health Center

CINCINNATIHoxworth Blood Center, the University of Cincinnati (UC) and Cincinnati Children's Hospital Medical Center will host the Midwest Symposium on New Concepts For Tissue-Specific Regenerative Medicine, Nov 17-18, 2012, in Rieveschl Auditorium of the Vontz Center for Molecular Studies.

The symposium, also being co-sponsored and co-funded by UC's Center for Clinical and Translational Science and Training (CCTST), will focus on research and collaboration regarding regenerative medicinethe process of regenerating human cells, tissues or organs to restore or establish normal function.

The field holds the promise of repairing damaged tissues and organs in the body by stimulating the body's own repair mechanisms or by growing replacement tissues in labs.

Jose Cancelas, MD, PhD, professor of pediatrics at the UC College of Medicine and director of the research division at Hoxworth Blood Center, is a co-organizer of the symposium and says regenerative medicine expertise is very strong in the region.

"The purpose of the symposium will be to create a forum where investigators and their groups can meet and share ideas and data," he says. "In addition, it will serve as an excellent platform for regional scientific interactions for investigators, postdocs and students that have interest in regenerative medicine and stem cell biology. Hopefully, this meeting will spark collaborations locally and regionally."

Specifically, the meeting will focus on research using stem cells in the body, or those manipulated in a petri dish, to study disease, generate therapeutic tissues and create genetic therapies.

Keynote speakers will deliver addresses followed by short oral presentations with extended discussions to allow interaction among attendees.

"Research presentations will span from how scientists are looking at the use of stem cells to assist with gastrointestinal, pancreas, lung, corneal, skeletal muscle, vascular and cardiac regeneration to genetic therapies and how this research could and is translating to treatment," Cancelas says. "There's a wealth of scientific and clinical stem cell work being done right here in Cincinnati.

View original post here:
Midwest regenerative medicine symposium to be held in Cincinnati

NHK - Japanese Govt. renews 10-year plan for iPS cell research
NHK World News ---- Nippon H #333;s #333; Ky #333;kai Description -- Japan #39;s science ministry has finalized a new 10-year plan to promote studies on iPS cell technology. iPS cells are made by reverting mature body cells into highly potent blank slates capable of growing into any kind of body cells. A ministry panel on Friday adopted a plan calling for the start of clinical trials using the cells next year or later to regenerate retinal functions. The plan calls for clinical application of iPS cell-derived heart muscles in 3 to 5 years. The ministry set a 10-year goal for developing technology to create lungs, kidneys and other organs from the cells. Among the panel #39;s members is Kyoto University Professor Shinya Yamanaka, who won this year #39;s Nobel Prize for his groundbreaking development of iPS cells. Yamanaka said putting regenerative medicine into clinical practice will require a lot of work. The ministry initially compiled a 10-year plan for iPS research in 2009, but decided to revise it as studies in the field have advanced rapidly in the past 3 years. Nov. 2, 2012 - Updated 09:13 UTC (18:13 JST)From:NHKReloadedViews:2 0ratingsTime:01:16More inScience Technology

Visit link:
NHK - Japanese Govt. renews 10-year plan for iPS cell research - Video

Saturday, Nov. 3, 2012

A science ministry working group studying stem cells and regenerative medicine has updated its road map on induced pluripotent stem-cell research, aiming to establish technologies to create organs including brains, lungs and kidneys via iPS cells within 10 years.

The group's updated plan, first compiled in 2009, calls for the distribution of iPS cells for regenerative medicine to start within the next two to three years. The announcement comes after Kyoto University professor Shinya Yamanaka jointly won this year's Nobel Prize in physiology or medicine for his revolutionary work in developing iPS cells.

The new road map includes a plan by the government-backed Riken research institute to begin a clinical study in fiscal 2013 on the transplantation of retinas created from iPS cells into patients suffering age-related deterioration in their vision.

In addition, a clinical study on heart muscle will start within three to five years, targeting patients who have suffered heart attacks or are experiencing other cardiac diseases. A study on brain nerve cells will meanwhile be launched in five to seven years, mainly for patients with Parkinson's disease.

Riken official Shinichi Nishikawa, also a member of the ministry's working group, said researchers from various fields should cooperate in compiling safety standards on the use of iPS cells. The science ministry has sought 8.7 billion for research related to regenerative medicine as part of its budget request for fiscal 2013.

Original post:
New iPS goal: brains, lungs, kidneys

ALAMEDA, Calif.--(BUSINESS WIRE)--

BioTime, Inc. (NYSE MKT: BTX) and its subsidiary OrthoCyte Corporation today announced the appointment of Francois Binette, PhD, as OrthoCytes Vice President of Research and Business Development. Dr. Binettes primary focus will be to develop and partner near- and long-term product opportunities in regenerative medicine with an emphasis on orthopedic diseases and injuries. OrthoCyte is a wholly owned subsidiary of BioTime, Inc. that develops cellular therapeutics for orthopedic repair, diseases, and injuries.

I am impressed by the robust nature of the novel and diverse progenitors of skeletal tissues that BioTime has isolated using its ACTCellerateTM technology, said Dr. Binette. The ability to generate scalable and precisely identified types of cartilage, bone, and tendon, combined with the HyStem technology for tissue engineering, gives us a remarkable platform for manufacturing an array of novel products to address some of the largest and fastest growing needs in the orthopedic space. I look forward to building on the science and technology developed at OrthoCyte to aggressively develop the companys product pipeline and pursue partnering opportunities.

Francois brings tremendous expertise in regenerative medicine, cell therapy, biologics, biomaterials, and combination medical devices. He also has significant business experience in partnering and collaboration with both start-up and large life science companies, said Michael D. West, PhD, BioTimes Chief Executive Officer. We welcome Francois to the OrthoCyte team and look forward to working together with him in developing commercial product opportunities for the orthopedic repair market.

Dr. Binette most recently was the founder of Rediens Inc., a Bay Area start-up company focused on chronic back pain therapies. Prior to establishing Rediens, he wasDirector of BiologicsR&D for the Spinal & Biologics business unit of Medtronic, Inc., and he also served in a variety of positions with Johnson & Johnson, where he focused on regenerative medicine therapies for various orthopedic indications, including cartilage injuries and back pain. Dr. Binette began his corporate career at Genzyme Tissue Repair, where he helped pioneer Carticel, the first FDA Biologic License Application-approved cell therapy product. Dr. Binette received his PhD in Biochemistry at Laval University in Qubec and was a postdoctoral research fellow at the LaJolla Cancer Research Foundation of the Sanford-Burnham Medical Research Institute and at MGH/Harvard Medical School. He is currently a fellow with the International Cartilage Repair Society.

About OrthoCyte Corporation

OrthoCyte Corporation (OrthoCyte), http://www.orthocyte.com, a subsidiary of BioTime, Inc., is a biotechnology company developing cell-based therapies for orthopedic disease. The company's lead product is OTX-CP07, monoclonal human embryonic progenitor cell lines for the repair of osteoarthritis. In addition, OrthoCyte has proprietary human embryonic stem cell-derived progenitors to skeletal muscle, tendon, and bone, all of which are in the preclinical phase of development.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is enhanced through subsidiaries focused on specific fields of application. BioTime develops and markets research products in the fields of stem cells and regenerative medicine, including a wide array of proprietary ACTCellerate cell lines, HyStem hydrogels, culture media, and differentiation kits. BioTime is developing Renevia (formerly known as HyStem-Rx), a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications. BioTime's therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need. BioTime's majority-owned subsidiary Cell Cure Neurosciences Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases. BioTime's subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries. Another subsidiary, OncoCyte Corporation, focuses on the diagnostic and therapeutic applications of stem cell technology in cancer, including the diagnostic product PanC-Dx currently being developed for the detection of cancer in blood samples. ReCyte Therapeutics, Inc. is developing applications of BioTime's proprietary induced pluripotent stem cell technology to reverse the developmental aging of human cells to treat cardiovascular and blood cell diseases. BioTime's subsidiary LifeMap Sciences, Inc. markets GeneCards, the leading human gene database, and is developing an integrated database suite to complement GeneCards that will also include the LifeMap database of embryonic development, stem cell research and regenerative medicine, and MalaCards, the human disease database. LifeMap will also market BioTime research products. BioTime's lead product, Hextend, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under exclusive licensing agreements. Additional information about BioTime can be found on the web at http://www.biotimeinc.com.

Forward-Looking Statements

See original here:
BioTime Subsidiary OrthoCyte Corporation Announces the Appointment of Francois Binette as Vice President

NEW YORK, Nov. 1, 2012 (GLOBE NEWSWIRE) -- The Stem for Life Foundation, NeoStem, Inc. (NYSE MKT:NBS), The Pontifical Council for Culture, and STOQ International today announced that they will host The Second International Vatican Adult Stem Cell Conference: Regenerative Medicine -- A Fundamental Shift in Science & Culture, from within The Vatican, April 11-13, 2013.

This event is part of a five-year collaboration between The Stem for Life Foundation, a not-for-profit organization devoted to raising global awareness of the therapeutic potential of adult stem cells, NeoStem, an emerging leader in the fast growing cell therapy industry, The Vatican's Pontifical Council for Culture and its foundation, called STOQ International (Science, Theology and the Ontological Quest).

With renowned journalists serving as moderators -- Meredith Vieira from NBC News, Bill Hemmer from The Fox News Channel, Peggy Noonan of The Wall Street Journal and Dr. Max Gomez from WCBS-TV -- The Second International Vatican Adult Stem Cell Conference will feature leading adult stem cell scientists and clinicians, thought leaders of faith, ethics and culture, business leaders as well as Ministers of Health, Ambassadors to The Holy See and regulatory officials from around the world. During the event, adult stem cell scientists and clinicians will present an array of medical advancements and ongoing research occurring throughout the world, including the ability to grow replacements for damaged and diseased organs; restoring heart function after heart attack; growing new skin for burn victims; rebalancing our own immune systems, pushing back a rising tide of chronic disease; advancements in cancer therapy; preventing organ rejection and addressing a range of other conditions and trauma, such as MS, traumatic brain injuries and cardiovascular disease via adult stem cell therapies. Throughout the event, patients will share their own stories of the unique, powerful treatments that have helped address their disease and reduce suffering.

"Regenerative medicine is poised to revolutionize disease management by finding new ways to boost the body's ability to heal itself. Whereas today treatment for many diseases is a matter of managing symptoms, regenerative medicine seeks to reverse the course of the disease by targeting its cause and repairing diseased or defective tissues or organs," said Dr. Robin Smith, President of The Stem for Life Foundation. "Not only will our conference educate people of all ages, religions and cultures on the potential of adult stem cells to treat chronic disease as part of this next great frontier, but we will generate a truly international dialogue on regenerative medicine, one that explores the interconnections between scientific breakthroughs, faith, culture and ethics."

The goals of the 2013 Second International Vatican Adult Stem Cell Conference are to:

"The developments within regenerative medicine are of great interest," said Msgr. Tomasz Trafny. "They show how science changes, causing paradigm shifts through interdisciplinary research. Cellular biology is a good example of such changes. These dynamics also cause deep cultural transformations on different levels, from health care to economy, from new technologies to legal issues. Thus, topics that apparently seem to be circumscribed only to strictly scientific discussions or theoretical ones, in fact modify our understanding of social dynamics, relationships and, in the ultimate analysis, our understanding of the human being. Today we acknowledge that insights from natural sciences play a crucial role in our society, having consequences for anthropology, philosophy and even theology. It is our mission and our duty to explore the above dynamics, to offer the best tools for pastoral care, and to encourage understanding of changing culture."

In June, The Pontifical Council for Culture and The Stem for Life Foundation presented the first copy of their forthcoming book, The Healing Cell: How The Greatest Revolution in Medical History is Changing Your Life, to The Holy Father, Pope Benedict XVI. The book is the result of a unique collaboration between the two organizations, and will be available in 2013. It includes a special address by His Holiness Benedict XVI, urging increased support and awareness for advancements in adult stem cell research in order to alleviate human suffering. To reserve a copy of the book, go to:http://www.stemforlife.org/healingcell

To learn more about The Second International Vatican Adult Stem Cell Conference please visit http://www.adultstemcellconference.org.

About The Pontifical Council for Culture

The Pontifical Council for Culture is that Dicastery of the Roman Curia which assists the Pope in the exercise of his supreme pastoral office for the benefit and service of the universal Church and of particular Churches concerning the encounter between the saving message of the Gospel and cultures, in the study of the weighty phenomena of the rift between the Gospel and cultures; indifference in matters of religion; unbelief. It is also concerned with relationships between the Church and the Holy See and the world of culture; in particular it promotes dialogue with contemporary cultures, so that human civilization may become increasingly open to the Gospel, and so that men and women of science, letters and the arts may know that the Church acknowledges their work as a service to truth, goodness and beauty. http://www.cultura.va

Link:
The Vatican's Pontifical Council for Culture, NeoStem, The Stem for Life Foundation & STOQ International Announce 'The ...

MARLBOROUGH, Mass.--(BUSINESS WIRE)--

Advanced Cell Technology, Inc. (ACT; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the Companys three ongoing clinical trials, has authorized the Company to move forward with enrollment and treatment of two additional patients with dry age-related macular degeneration (dry AMD). ACT will screen and enroll the second and third patients of the three-patient second cohort in the trial. Per trial protocol, each patient will be injected with 100,000 human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells.

Dry AMD represents one of the largest unmet medical needs in the world, and we are thrilled to be making steady progress in our clinical trial for this condition, commented Gary Rabin, ACTs chairman and CEO. We are well on our way to the halfway point of all three of our clinical trials. We also recently secured DSMB approval to complete the second cohort of our two trials for Stargardts Macular Dystrophy.

ACT is conducting three clinical trials in the U.S. and Europe using hESC-derived RPE cells to treat forms of macular degeneration, dry AMD and Stargardts Macular Dystrophy (SMD). Each trial will enroll a total of 12 patients, with cohorts of three patients each in an ascending dosage format, from 50,000 to 200,000 hESC-derived RPE cells. These trials are prospective, open-label studies, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD or SMD at 12 months, the studys primary endpoint.

This authorization to treat the next two patients in the second, higher-dosage cohort of our trial for dry AMD represents a notable milestone for our clinical programs, commented Robert Lanza, M.D., ACTs chief scientific officer. We look forward to treating these two patients and moving on to the third cohort in good time.

Further information about patient eligibility for ACTs SMD studies in the U.S. and E.U. as well as its dry AMD study in the U.S. are available atwww.clinicaltrials.gov,with the following Identifiers: NCT01345006 (U.S. SMD), NCT01469832 (E.U. SMD), and NCT01344993 (dry AMD).

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words will, believes, plans, anticipates, expects, estimates, and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the companys periodic reports, including the report on Form 10-K for the year ended December 31, 2011. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the companys management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Companys clinical trials will be successful.

Visit link:
ACT Announces Data and Safety Monitoring Board (DSMB) Approval to Complete Second Patient Cohort in Clinical Trial for ...

HOLLISTON, Mass., Nov. 1, 2012 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (HBIO), a global developer, manufacturer, and marketer of a broad range of tools to advance life science research and regenerative medicine, today reported unaudited financial results for the three and nine months ended September 30, 2012.

Third Quarter Reported Results

Revenues for the three months ended September 30, 2012 were $26.1 million, a decrease of $0.3 million, or 1.0% compared to revenues of $26.4 million for the three months ended September 30, 2011. Currency exchange rates had a negative 1.4% effect on revenues in the third quarter of 2012 compared with the third quarter of 2011. Our acquisition of AHN Biotechnologie GmbH ("AHN") in February 2012 had a positive 1.6% effect on revenues. Excluding the effects of currency changes and acquisitions, our third quarter revenues decreased 1.2% from the same period last year.

Net (loss) income, as measured under U.S. generally accepted accounting principles ("GAAP"), was a $133,000 loss, or $0.00 per diluted share for the three months ended September 30, 2012 compared to a $28,000 income, or $0.00 per diluted share, for the same period in 2011. The unfavorable year-to-year quarterly GAAP earnings comparison was primarily due to increased spending of $0.7 million (pre-tax) in our development-stage Regenerative Medicine Device ("RMD") business.

On a non-GAAP adjusted basis, earnings per share for our core Life Science Research Tools ("LSRT") business for the three months ended September 30, 2012 was $0.08 per diluted share, compared with $0.07 per diluted share for the same period in 2011. Non-GAAP adjusted earnings per share for our RMD business for the third quarter of 2012 was a loss of $0.04 per diluted share, compared with a loss of $0.02 per diluted share for the third quarter of 2011, and reflected greater activities in developing this initiative. Our total non-GAAP adjusted earnings per share, reflecting LSRT and RMD combined, was $0.04 per diluted share for the third quarter of 2012 compared with $0.05 per diluted share for the third quarter of 2011.

Year to Date Reported Results

Revenues for the nine months ended September 30, 2012 were $82.9 million, an increase of $3.1 million, or 3.9% compared to revenues of $79.8 million for the nine months ended September 30, 2011. Currency exchange rates had a negative 1.5% effect on revenues for the nine months ended September 30, 2012, compared with the same period in the previous year. Our acquisitions of CMA Microdialysis AB ("CMA") in July 2011 and AHN in February 2012 had a positive 3.7% effect on revenues. Excluding the effects of currency changes and acquisitions, our organic revenue growth for the nine months ended September 30, 2012 was 1.7% over the same period in the previous year.

Net income, as measured under GAAP, was $1.2 million, or $0.04 per diluted share for the nine months ended September 30, 2012 compared to $3.1 million, or $0.10 per diluted share, for the same period in 2011. The unfavorable year-to-year quarterly GAAP earnings comparison was primarily due to increased activity and spending in our development-stage RMD business.

On a non-GAAP adjusted basis, earnings per share for our core LSRT business for the nine months ended September 30, 2012 was $0.28 per diluted share, compared with $0.25 per diluted share for the same period in 2011. Non-GAAP adjusted earnings per share for our RMD business for the nine months ended September 30, 2012 was a loss of $0.11 per diluted share, compared with a loss of $0.05 per diluted share for the same period in 2011, and reflected greater activities in developing this initiative. Our total non-GAAP adjusted earnings per share, reflecting LSRT and RMD combined, were $0.17 per diluted share for nine months ended September 30, 2012 compared with $0.20 per diluted share for the same period in 2011.

Commenting on the Company's performance, Chane Graziano, CEO, stated, "In the month of September, we saw a decrease in demand for our products primarily in the university/government research market. It is apparent the researchers were conserving their current budgets due to the uncertainty of the level of future funding in this political/economic environment. This had an impact on our third quarter performance."

See the article here:
HBIO Reports Third Quarter 2012 Results

Tweet the Lords Science Committee your questions for eye, heart and Parkinson #39;s disease experts
The House of Lords Science and Technology Committee will next week take evidence from leading experts on heart disease, eye conditions and Parkinson #39;s disease. They want to hear what questions most concern the public, using the social media website http://www.twitter.com The Session is part of the Committee #39;s inquiry into Regenerative Medicine and the Committee are asking the public to tweet questions using the hashtag #RegenMedQs. The aim of the session is to help sift the hype from the reality when it comes to the prospects of regenerative medicine. Lord Krebs the Committee Chairman has made an appeal on YouTube for the public to get involved. For more information visit: http://www.parliament.ukFrom:UKParliamentViews:263 3ratingsTime:01:18More inNews Politics

Original post:
Tweet the Lords Science Committee your questions for eye, heart and Parkinson's disease experts - Video

Newgate Comms regenerative medicine event
Newgate Communications hosted the annual technology day for our client Tissue Regenix. It was an event showcasing the latest developments of the company and brought together analysts, investors and journalists. We commissioned a video of the event for Tissue Regenix - which you can see on their YouTube channel. This video was produced in-house by Newgate and shows our ability to produce short films on behalf of our clients (we did the photography too!)From:NewgateCommsViews:19 0ratingsTime:01:57More inNews Politics

See the rest here:
Newgate Comms regenerative medicine event - Video

Sharon Shepherd ACNP - A4M Fellowship
Meet Sharon Shepherd, ACNP, from the A4M Fellowship in Anti-Aging Regenerative MedicineFrom:Phil GrindstoneViews:8 0ratingsTime:03:16More inPeople Blogs

View post:
Sharon Shepherd ACNP - A4M Fellowship - Video

Update in Preventative / Regenerative Medicine - by Ron Rothenberg, MD
Update in Preventative/Regenerative Medicine -- Inflammation, Hormones, Stem Cells and Telomeres- by Ron Rothenberg, MD on August 2012 Visit the Silicon Valley Health Institute (aka Smart Life Forum) at http://www.svhi.comFrom:Mike KorekViews:6 0ratingsTime:01:40:35More inScience Technology

Continue reading here:
Update in Preventative / Regenerative Medicine - by Ron Rothenberg, MD - Video

Regenerative Medicine - How It #39;s Made Minisodes
How Regenerative Medicine are madeFrom:Santhosh SuryavanshiViews:1 0ratingsTime:05:00More inScience Technology

Read more:
Regenerative Medicine - How It's Made Minisodes - Video

Gov. Perry Speaks at the Inaugural Houston Stem Cell Summit
10/26/2012 - HOUSTON - Gov. Rick Perry highlighted Texas #39; leading role in the advancement of regenerative medicine to produce safe, effective and ethical adult stem cell therapies. The governor spoke at the inaugural Houston Stem Cell Summit, which focuses on adult stem cell research and its potential to tackle life-threatening diseases. for more information: governor.state.tx.usFrom:govperryViews:128 0ratingsTime:22:30More inNews Politics

View post:
Gov. Perry Speaks at the Inaugural Houston Stem Cell Summit - Video

Stem cell commercialization panel discussion
How can companies make a business out of regenerative medicine, now that the science looks increasingly solid. Panel discussion Monday, Oct, 29 at Stem Cell Meeting on the Mesa tackles this. Speaking in this clip are are Dean Tozer of Shire Regenerative Medicine (pin-striped suit), Jay Siegel, Janssen Pharmaceutical Cops, (dark blue suit and tie), and Greg Lucier, Life Technologies, (lighter blue suit and tie), the moderator.From:Bradley FikesViews:85 0ratingsTime:06:43More inScience Technology

More:
Stem cell commercialization panel discussion - Video

Stem Cell Meeting on the Mesa
The 2012 Stem Cell Meeting on the Mesa is a three-day conference aimed at bringing together senior members of the business development and scientific research communities in regenerative medicine to advance stem cell science into cures for debilitating diseases and injuries. The meeting features a nationally recognized Scientific Symposium attended by more than 600 leading scientists and researchers along side the regenerative medicine industry #39;s premier annual Investor and Partnering Forum designed to facilitate a bridge between academia and industry through one-on-one meetings and further the translation of clinical research. Scientific Meeting Agenda at a Glance 8:00 am -- Welcome Remarks Alan Trounson, President, California Institute for Regenerative Medicine 8:15 am -- Morning Keynote Speaker ** NO FILMING - Speaker did not consent to being recorded. Michele De Luca, Professor, Director, Centre for Regnerative Medicine, University of Modena and Reggio Emilia; Scientific Director, Holostem Terapie Avanzate Srl 8:45 am -- Panel 1: Cancer and Cancer Stem Cells Chair: Robert Wechsler-Reya, Professor, Director, Tumor Development Program, Sanford-Burnham Medical Research Institute Panelists: Jeremy Rich, Chairman, Department of Stem Cell Biology and Regenerative Medicine, The Cleveland Clinic Luke Lairson, Assistant Professor, The Scripps Research Institute Ben Spike, Senior Research Associate, Salk Institute for Biological Studies Catriona Jamieson, Associate Professor ...From:SalkInstituteViews:50 0ratingsTime:00:00More inScience Technology

View post:
Stem Cell Meeting on the Mesa - Video

SENS Talk - Dr. Aubrey de Grey gives a lecture at the University of Delaware
Dr. Aubrey de Grey from the SENS Foundation gives a talk on regenerative medicine at the University of Delaware on October 2, 2012. He is introduced by Marvin Whitaker, who is President of the Socratic Club and is a PhD student in the Department of Political Science and International Relations at the University of Delaware. This event was hosted by the Socratic Club and co-hosted by the University of Delaware #39;s Center for Science, Ethics, and Public Policy.From:Socratic ClubudelViews:126 5ratingsTime:01:16:40More inScience Technology

Go here to read the rest:
SENS Talk - Dr. Aubrey de Grey gives a lecture at the University of Delaware - Video

Regenerative medicine from an engineering perspective
The Miyata Group at Keio University is doing research that helps with regenerative medicine, by looking at cells and tissues from the viewpoint of engineering. Q. Growing cells, bone, and cartilage outside the body is usually done just by culturing them, using in jelly- or sponge-like materials. In that case, the cells themselves form 3D tissue from nutrients in the culture medium, resulting in block-like solids. However, the strength and hardness of the tissue are by no means sufficient. Currently, the strength obtained is ten to a hundred times less than that of similar materials in the human body. Our approach is to try giving the materials some kind of stimulus -- in particular, a physical or mechanical stimulus. When making cartilage from cells grown outside the body, we wondered if we could produce harder, stronger cartilage by compressing the cell-containing hydrogel rhythmically, at the same frequency as in walking. The Miyata Group designed, built, and tested their own machine for giving cells a compressive stimulus at the same frequency as walking. Compared with cartilage cells grown in hydrogel without the stimulus, the resulting cartilage was twice as hard. In another project, the researchers are working on cell sorting technology, to separate cells with a therapeutic effect from among all the cultured cells. Q. Currently, there are commercially available technologies that use fluorescent pigments, magnetic particles, and magnetic beads. But equipment like ...From:keiouniversityViews:0 2ratingsTime:04:25More inScience Technology

See the original post here:
Regenerative medicine from an engineering perspective - Video

George Brown of Kool The Gang Talks About His Stem Cell Treatment At MetroMD Hollywood
Musician George Brown, an original member of the jazz funk band, Kool and The Gang, talks with us about his day at MetroMD. George was in Los Angeles on tour with rockers Van Halen David Lee Roth in June 2012. George had an orthopedic stem cell treatment performed by Dr. Alex Martin MD at about noon and was on stage performing 8 hours later. For more info, visit us at MetroMD.net or call (323) 285-5300. The MetroMD Institute of Regenerative Medicine is located in Hollywood at the heart of Los Angeles.From:MetroMDViews:6 0ratingsTime:02:02More inScience Technology

Read more:
George Brown of Kool

Can Adults Grow Taller With HGH (Human Growth Hormone)?
MetroMD.net Because of the overwhelming success of Human Growth Hormone (HGH) Therapy in effecting growth in short-statured children, adults often ask whether the treatment will work for them also. Dr. Martin explains the function of our body #39;s growth plates and how these determine future growth potential. For more info, visit us at http or call (323) 285-5300. The MetroMD Institute of Regenerative Medicine is located in Hollywood at the heart of Los Angeles.From:MetroMDViews:8 0ratingsTime:02:55More inScience Technology

See original here:
Can Adults Grow Taller With HGH (Human Growth Hormone)? - Video